0.790
-0.03 (-3.66%)
AIStockmoo Score
| Value 30% | -0.6 |
| Earns below its cost of capital. Returns on capital rising. info | |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -4.4 |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | -1.4 |
| Institutions net -1.84% of shares in their latest 13F filings: 5 holders increased, 9 decreased (quarter to 30 Sep 2026). info | |
| Short interest -82.7% from 31 Aug to 30 Oct 2026, 1 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Levels trending down. info | |
| Final Score | -2.52 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | IN8bio, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| INAB | - | - | - | 0.570 | -2.5 |
| HLVX | 103 M | - | - | 0.710 | 0.0 |
| MEIP | 49 M | - | - | - | 0.0 |
| SONN | 33 M | - | - | 2.07 | -1.4 |
| ANIX | - | - | - | 6.26 | -1.6 |
| PLRX | - | - | - | 0.320 | -3.8 |
Select this tab to load the latest available analysis.
|
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.20% |
| % Held by Institutions | 20.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Texas Capital Bank Wealth Management Services Inc | 30 Sep 2026 | 23,521 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 34.95%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 5 | 72,270 |
| Decreased | 9 | 189,613 |
| New | 2 | 10,936 |
| Sold out | 2 | 96,337 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 15,733 | 1.0 |
| 15 Oct 2026 | 32,797 | 1.0 |
| 30 Sep 2026 | 46,440 | 1.0 |
| 15 Sep 2026 | 63,110 | 2.2 |
| 31 Aug 2026 | 90,842 | 1.6 |
| 14 Aug 2026 | 139,903 | 1.4 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0… |
| 06 Nov 2026 | Yahoo Finance |
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the… |
| 05 Nov 2026 | Yahoo Finance |
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentReceived third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune diseaseRemain… |
| 22 Sep 2026 | Yahoo Finance |
IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and… |
| 10 Sep 2026 | Yahoo Finance |
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and… |
| 09 Sep 2026 | Yahoo Finance |
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance… |
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |